Yayın:
The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registry

Basit Görünüm
dc.contributor.authorUslu, Sadettin
dc.contributor.authorCan, Gerçek
dc.contributor.authorŞenel, Soner
dc.contributor.authorİnanç, Nevsun
dc.contributor.authorAkar, Servet
dc.contributor.authorKocaer, Sinem Burcu
dc.contributor.authorBirlik, Merih
dc.contributor.authorÇapar, Sedat
dc.contributor.authorAkkoç, Nurullah
dc.contributor.authorÖnen, Fatoş
dc.contributor.buuauthorDalkılıç, Ediz
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentRomatoloji Bilim Dalı
dc.date.accessioned2024-01-09T12:29:32Z
dc.date.available2024-01-09T12:29:32Z
dc.date.issued2018-06
dc.descriptionBu çalışma, 13-16 Haziran 2018 tarihlerinde Amsterdan[Hollanda]’da düzenlenen Congress of the European-League-Against-Rheumatism (EULAR) Kongresi‘nde bildiri olarak sunulmuştur.
dc.description.sponsorshipEuropean League Against Rheumatism
dc.identifier.citationUslu, S. vd. (2018). ''The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registry''. Annals of the Rheumatic Diseases, 77(Supplement 2), 329-329.
dc.identifier.doi10.1136/annrheumdis-2018-eular.6440
dc.identifier.endpage329
dc.identifier.issn0003-4967
dc.identifier.issn1468-2060
dc.identifier.issueSupplement 2
dc.identifier.startpage329
dc.identifier.urihttps://doi.org/10.1136/annrheumdis-2018-eular.6440
dc.identifier.urihttps://ard.bmj.com/content/77/Suppl_2/329
dc.identifier.urihttps://hdl.handle.net/11452/38904
dc.identifier.volume77
dc.identifier.wos000444351001026
dc.indexed.wosSCIE
dc.indexed.wosCPCIS
dc.language.isoen
dc.publisherBMJ Publishing Group
dc.relation.collaborationYurt içi
dc.relation.journalAnnals of the Rheumatic Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRheumatology
dc.subject.wosRheumatology
dc.titleThe efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registry
dc.typeArticle
dc.wos.quartileQ1 (Rheumatology)
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Romatoloji Bilim Dalı
local.indexed.atPubMed

Dosyalar

Orijinal seri

Şimdi gösteriliyor 1 - 1 / 1
Küçük Resim
Ad:
Dalkılıç_vd_2018.pdf
Boyut:
168.82 KB
Format:
Adobe Portable Document Format
Açıklama
İndir

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama
İndir

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications